Table 2 Characteristics of included trials for meta-analysis for OS

Lead author (y)	Trial name (phase)	TKI	Chemotherapy	EGFR mutation	Sample size (TKI/chemotherapy)	HR for OS (TKI vs chemotherapy) mean (95% CI)
Fukuoka et al (2011)	IPASS (III)	Gefitinib 250 mg per day	Carboplatin (AUC=5 or 6) Paclitaxel (200 mg m⁻²) every 3 weeks for ⩽6 cycles^a	Del 19 L858R	Not available Not available	0.79 (0.54–1.15) 1.44 (0.90–2.30)
Inoue et al (2013)	NEJ002 (III)	Gefitinib 250 mg per day	Carboplatin (AUC=6) Paclitaxel (200 mg m⁻²) every 3 weeks for ⩾3 cycles	Del 19 L858R	58/59 49/48	0.83 (0.52–1.34) 0.82 (0.49–1.38)
EURTAC (2013) ^c	EURTAC (III)	Erlotinib 150 mg per day	Cisplatin (75 mg m⁻²) on day 1 Docetaxel (75 mg m⁻²) on day 1 or gemcitabine (1250 mg m⁻²) on day 1 and 8, every 3 weeks for 4 cycles^b	Del 19 L858R	57/58 29/29	0.94 (0.57–1.54) 0.99 (0.56–1.76)
Yang et al (2015)	LUX-Lung 3 (III)	Afatinib 40 mg per day	Cisplatin (75 mg m⁻²) Pemetrexed (500 mg m⁻²) every 3 weeks for ⩽6 cycles	Del 19 L858R	112/57 91/47	0.54 (0.36–0.79) 1.30 (0.80–2.11)
Yang et al (2015)	LUX-Lung 6 (III)	Afatinib 40 mg per day	Cisplatin (75 mg m⁻²) on day 1 Docetaxel (75 mg m⁻²) on day 1 or gemcitabine (1000 mg m⁻²) on day 1 and 8, every 3 weeks for ⩽6 cycles	Del 19 L858R	124/62 92/46	0.64 (0.44–0.94) 1.22 (0.81–1.83)

Abbreviations: AUC=area under curve; CI=confidence interval; EGFR=epidermal growth factor receptor; HR=hazard ratio; OS=overall survival; TKI=tyrosine kinase inhibitor.
^aAUC is the dose equivalent to an area under the concentration-time curve.
^bPatients who were ineligible for cisplatin treatment received intravenous carboplatin chemotherapy instead (3-week cycles of AUC 6 on day 1 with 75 mg m⁻² docetaxel on day 1, or AUC 5 on day 1 with 1000 mg m⁻² gemcitabine on days 1 and 8).
^cTARCEVA (erlotinib) prescribing information 2013 from drug company.

Quick links

Search